Menu

DeNovix: CellDrop Slide-Free Cell Counter

Experience the difference of counting cells without a slide

Feb 21, 2019
The Scientist Creative Services Team
Are you ready to count without slides?

Slide-based cell counting is a tried and true laboratory technique, but it's also prone to artifact and inaccuracy. Doing away with slides might seem drastic, but it can improve your analysis quality, throughput, and speed. Don't you owe it to your research to step into the future of cell counting with the DeNovix CellDrop system? Learn more at www.denovix.com/celldrop.

March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

The Complex Biology of Macrophages: Origins, Functions, and Activation States
The Complex Biology of Macrophages: Origins, Functions, and Activation States
Download this poster from R&D Systems for a detailed overview of macrophage markers, functions, development, specialization, and activation!
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Download this guide from BellBrook Labs to learn about how to use Transcreener® biochemical assays to measure drug-target residence times, complete with examples and case studies!
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
After visiting labs around the world to identify ways to advance its industry-leading cell counting technology, Beckman Coulter Life Sciences will host a live streaming event on March 26 at 10 a.m. EDT / 7 a.m. PDT to announce its latest product innovation.  
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.